[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Sadahiro S, Suzuki T, Ishikawa K, Yasuda S, Tajima T, Makuuchi H, Saitoh T, Murayama C: Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial. Cancer; 2004 Feb 1;100(3):590-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.
  • BACKGROUND: The liver is the most frequent site of recurrence after curative resection in patients with colon carcinoma.
  • For liver metastasis, a high response rate can be achieved with hepatic arterial infusion (HAI) chemotherapy.
  • In the current study, the authors administered 5-fluorouracil (5-FU) as adjuvant chemotherapy by HAI to patients with colon carcinoma without liver metastases and studied its effects on recurrence in the liver and survival.
  • METHODS: A total of 316 patients with preoperative Stage II or Stage III colon carcinoma (according to the 1997 revision of the International Union Against Cancer TNM staging system) were randomly assigned to receive surgery plus 3-week continuous HAI of 5-FU or surgery alone.
  • The primary endpoint was disease-free survival, whereas the secondary endpoints were overall survival and liver metastasis-free survival.
  • RESULTS: There were no significant differences noted in morbidity between the two treatment arms.
  • During the follow-up period (median, 59.0 months), the incidence of liver metastasis was significantly decreased in the HAI arm whereas there were no significant differences reported between the 2 arms with regard to the frequency of metastasis at other sites.
  • In the HAI arm, the risk ratio for recurrence was 0.40 (95% confidence interval [95% CI], 0.24-0.64; P=0.0002), the risk ratio for death was 0.37 (95% CI, 0.21-0.67; P=0.0009), and the risk ratio for liver metastasis was 0.38 (95% CI, 0.22-0.66; P=0.0005).
  • CONCLUSIONS: A schedule of 3-week HAI of 5-FU given as adjuvant chemotherapy to patients with Stage III colon carcinoma appeared to contribute to a significant decrease in the frequency of liver metastases and was associated with an improved survival rate.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Fluorouracil / administration & dosage. Liver Neoplasms / prevention & control
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Chi-Square Distribution. Colectomy / methods. Combined Modality Therapy. Female. Follow-Up Studies. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Primary Prevention / methods. Probability. Reference Values. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • [CommentIn] Cancer. 2004 Feb 1;100(3):437-40 [14745858.001]
  • (PMID = 14745877.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, McMillan DC: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer; 2007 Nov 5;97(9):1266-70
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer.
  • There is increasing evidence that the presence of a systemic inflammatory response plays an important role in predicting survival in patients with colorectal cancer.
  • The aim of the present study was to compare the prognostic value of an inflammation-based prognostic score (modified Glasgow Prognostic Score (Mgps) 0=C-reactive protein <10 mg l(-1), 1=C-reactive protein >10 mg l(-1), and 2=C-reactive protein >10 mg l(-1) and albumin<35 g l(-1)) with that of components of the white cell count (neutrophils, lymphocytes, monocytes and platelets using standard thresholds) in patients with colorectal cancer.
  • Two patient groups were studied: 149 patients who underwent potentially curative resection for colorectal cancer and 84 patients who had synchronous unresectable liver metastases.
  • In those patients who underwent potentially curative resection the minimum follow-up was 36 months and 20 patients died of their cancer.
  • On multivariate survival analysis only TNM stage (HR 3.75, 95% CI 1.54-9.17, P=0.004), monocyte count (HR 3.79, 95% CI 1.29-11.12, P=0.015) and mGPS (HR 2.21, 95% CI 1.11-4.41, P=0.024) were independently associated with cancer-specific survival.
  • In patients with synchronous unresectable liver metastases the minimum follow-up was 6 months and 71 patients died of their cancer.
  • On multivariate survival analysis only single liver metastasis >5 cm (HR 1.78, 95% CI 0.99-3.21, P=0.054), extra-hepatic disease (HR 2.09, 95% CI 1.05-4.17, P=0.036), chemotherapy treatment (HR 2.40, 95% CI 1.82-3.17, P<0.001) and mGPS (HR 1.44, 95% CI 1.01-2.04, P=0.043) were independently associated with cancer-specific survival.
  • In summary, markers of the systemic inflammatory response are associated with poor outcome in patients with either primary operable or synchronous unresectable colorectal cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Inflammation Mediators / metabolism
  • [MeSH-minor] Aged. Female. Humans. Leukocyte Count. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):861-8 [10737287.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):881-6 [17245566.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):617-23 [11005561.001]
  • [Cites] Ann Intern Med. 2000 Oct 17;133(8):622-34 [11033592.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):331-5 [11875693.001]
  • [Cites] Br J Surg. 2002 May;89(5):586-90 [11972548.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):64-9 [12094630.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):215-9 [12555298.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1028-30 [12966420.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1704-6 [15150622.001]
  • [Cites] Cancer. 1970 Jan;25(1):135-40 [5410303.001]
  • [Cites] JAMA. 1982 Feb 19;247(7):1004-6 [7035703.001]
  • [Cites] J R Coll Surg Edinb. 1998 Jun;43(3):163-8 [9654876.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):64-70 [9671068.001]
  • [Cites] Am J Surg. 1998 Oct;176(4):335-8 [9817250.001]
  • [Cites] N Engl J Med. 1999 Feb 11;340(6):448-54 [9971870.001]
  • [Cites] J Surg Oncol. 2005 Sep 1;91(3):181-4 [16118772.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6240-8 [16135490.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):227-30 [16404432.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):637-41 [16479253.001]
  • [Cites] Support Care Cancer. 2006 Oct;14(10):999-1011 [16708213.001]
  • [Cites] Pancreatology. 2006;6(5):450-3 [16847382.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):205-12 [17149754.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):222-5 [17211465.001]
  • [Cites] J Support Oncol. 2007 Apr;5(4):157-62; discussion 164-6, 183 [17500503.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):83-91 [10813129.001]
  • (PMID = 17923866.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Inflammation Mediators
  • [Other-IDs] NLM/ PMC2360467
  •  go-up   go-down


3. van Vliet EP, Eijkemans MJ, Steyerberg EW, Kuipers EJ, Tilanus HW, van der Gaast A, Siersema PD: The role of socio-economic status in the decision making on diagnosis and treatment of oesophageal cancer in The Netherlands. Br J Cancer; 2006 Nov 6;95(9):1180-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of socio-economic status in the decision making on diagnosis and treatment of oesophageal cancer in The Netherlands.
  • In the United States (USA), a correlation has been demonstrated between socio-economic status (SES) of patients on the one hand, and tumour histology, stage of the disease and treatment modality of various cancer types on the other hand.
  • It is unknown whether such correlations are also involved in patients with oesophageal cancer in The Netherlands.
  • Between 1994 and 2003, 888 oesophageal cancer patients were included in a prospective database with findings on the diagnostic work-up and treatment of oesophageal cancer.
  • Multivariable logistic regression analysis showed no correlation between SES and staging procedures and preoperative TNM stage.
  • Patients with a higher SES more frequently underwent resection or were treated with chemotherapy (OR: 1.15; 95% CI 1.01-1.32 and OR: 1.16; 95% CI 1.02-1.32, respectively).
  • Socio-economic factors are involved in oesophageal cancer in The Netherlands, as patients with a higher SES are more likely to have an adenocarcinoma and patients with a lower SES a squamous cell carcinoma.
  • Moreover, the correlations between SES and different treatment modalities suggest that both patient and doctor determinants contribute to the decision on the most optimal treatment modality in patients with oesophageal cancer.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Social Class
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Databases as Topic / statistics & numerical data. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Netherlands. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Care. 2002 Jan;40(1 Suppl):I14-26 [11789626.001]
  • [Cites] Surg Oncol. 2001 Nov;10(3):103-11 [11750229.001]
  • [Cites] South Med J. 2002 Aug;95(8):900-8 [12190229.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Med Care. 2003 Jul;41(7):842-52 [12835608.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2):235-43 [14762861.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):601-9 [15280639.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] Scand J Public Health. 2004;32(4):250-6 [15370764.001]
  • [Cites] N Engl J Med. 1988 Mar 10;318(10):612-7 [2830514.001]
  • [Cites] Gastrointest Radiol. 1992 Fall;17(4):305-10 [1426845.001]
  • [Cites] Am J Surg. 1993 May;165(5):558-60 [8488936.001]
  • [Cites] Chest. 1998 Mar;113(3):687-95 [9515844.001]
  • [Cites] Br J Surg. 1998 Jul;85(7):994-8 [9692582.001]
  • [Cites] Med Care. 1998 Sep;36(9):1337-48 [9749657.001]
  • [Cites] Health Policy. 1998 Sep;45(3):221-38 [10338953.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):20-9 [9934727.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1198-205 [10519898.001]
  • [Cites] Laryngoscope. 2005 Jan;115(1):125-31 [15630380.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):510-7 [15659496.001]
  • [Cites] Health Econ. 2005 Jun;14(6):595-608 [15497191.001]
  • [Cites] Soc Sci Med. 2006 Jan;62(2):317-28 [16039765.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):234-42 [16454824.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2378-90 [10590381.001]
  • [Cites] Ethn Dis. 2000 Spring-Summer;10(2):248-56 [10892832.001]
  • [Cites] Clin Radiol. 2000 Sep;55(9):696-701 [10988048.001]
  • [Cites] Am J Epidemiol. 2001 Jan 15;153(2):114-22 [11159155.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Med Care. 2002 Aug;40(8):717-24 [12187185.001]
  • (PMID = 17031405.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360583
  •  go-up   go-down


Advertisement
4. Chen WJ, Kuo JY, Chen KK, Lin AT, Chang YH, Chang LS: Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital. J Chin Med Assoc; 2005 Nov;68(11):522-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor staging was according to the 2002 AJCC TNM classification and stage groupings.
  • RESULTS: There were 69 males and 42 females, with a mean age of 70.5 +/- 9.4 years at diagnosis.
  • Nephroureterectomy with bladder cuff excision was performed in 78 patients, 12 patients received segmental resection of the ureter, 4 received ureteroscopic laser coagulation, and 17 underwent chemotherapy or radiotherapy or both.
  • Disease recurrence in the nephroureterectomy group occurred in 36 patients (46.2%), with 17 (21.8%) at the urinary bladder, 2 (2.6%) at the retroperitoneum, 1 (1.3%) at the contralateral ureter, 6 (7.7%) with distant metastases to the lung, bone, distant lymph nodes or liver, and 10 (12.8%) at multiple sites.
  • The 5-year cancer-specific survival rate was 100% for pTa/is, 95.2% for pT1, 69.4% for pT2, and 43.8% for pT3.
  • All 3 pT4 cases died of cancer in a median of 12 months.
  • Significant prognostic factors for cancer-specific survival by univariate analysis were pT (p = 0.00001), stage (p = 0.00001), type of treatment (p = 0.00001) and grade (p = 0.0001).
  • On multivariate analysis, only stage (p = 0.0001) and grade (p = 0.014) were significant for cancer-specific and overall survival.
  • Tumor stage and grade are the only significant prognostic factors for both cancer-specific and overall survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323396.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


5. Zhang Z, Fan S: [Liver transplantation for hepatocellular carcinoma: a report of 8 patients]. Zhonghua Wai Ke Za Zhi; 2000 Jun;38(6):415-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplantation for hepatocellular carcinoma: a report of 8 patients].
  • OBJECTIVE: To evaluate the feasibility of liver transplantation as a treatment for hepatocellular carcinoma (HCC).
  • METHODS: From July 1995 to October 1998, eight liver cancer patients with cirrhosis underwent liver transplantation in Queen Mary Hospital.
  • The liver grafts were obtained from 6 brainstem dead donors and 2 living donors.
  • Five patients had known HCC and 3 had incidental tumor identified in the explanted liver.
  • TNM staging: stage II (5 cases), stage III (2 cases) and stage IV a (1 case).
  • After liver transplantation, the patients were followed up prospectively for a median of 36 months.
  • Except for one patient who had preoperative chemotherapy, no anticancer treatment was given before and after transplantation.
  • RESULTS: Three patients had acute rejection, 5 developed complication in early post transplantation.
  • CONCLUSIONS: Liver transplantation is a feasible method for treatment of HCC in selected patients.
  • Living donor liver transplantation can overcome the problems of donor shortage and tumor growth while waiting for liver transplantation.
  • [MeSH-major] Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11832071.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC: Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. Eur J Cancer; 2009 Jun;45(9):1630-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.
  • The aim of this study was to compare six prognostic staging systems (Okuda stage, TNM stage, CLIP score, BCLC stage, JIS score and Tokyo score) in predicting survival in patients with hepatocellular carcinoma (HCC).
  • Demographic, laboratory and tumour characteristics were determined at diagnosis.
  • CLIP score was the best fit system for HCC patients receiving chemotherapy or supportive care.
  • Each staging system showed a significant difference in predicting the probability of survival across different stages.
  • The applicability of staging systems for patients with HCC was dependent on treatment methods.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157858.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Cortesi E, Tuzi A, Musio D: [Extraperitoneal rectal cancer: chemo-radiotherapy treatments]. Ann Ital Chir; 2010 Jul-Aug;81(4):247-54; discussion 283
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extraperitoneal rectal cancer: chemo-radiotherapy treatments].
  • PURPOSE: The determination of the best therapeutic approach in extraperitoneal rectal cancer patients is very complex both in the neoadjuvant/adjuvant and the metastatic setting.
  • We tried to identify and summarize the current methods of diagnosis, staging and treatment from a multidisciplinary approach.
  • METHODS: Five sections can be indentified: diagnosis and staging; neoadjuvant treatment; adjuvant treatment; liver metastases treatment and local recurrence therapy Data were collected from international guidelines (NCCN) and MEDLINE search.
  • The main aim was the identification of the beast diagnostic and therapeutic approach in extraperitoneal rectal cancer patients in case of local recurrence and metastatic disease.
  • Three articles dealt with staging procedures, 24 dealt with neoadjuvant and adjuvant therapy; 18 were about with liver metastases and 3 about local recurrence treatment.
  • CONCLUSIONS: The correct disease staging is necessary for pursuing the best therapeutic approach and it should involve different radiological techniques in order to evaluate the clinic TNM.
  • Neoadjuvant treatment (chemo-radiotherapy) should be considered for stage II and stage III extraperitoneal rectal cancer patients, followed by post-operative adjuvant chemotherapy.
  • Patients who underwent surgery and have a post-operative stage II or III disease, have to receive four months of adjuvant chemotherapy after surgical resection.
  • Initial treatment options of asymptomatic patient with resectable liver metases include systemic chemotherapy in' order to obtain downstaging of the primary tumor and liver metastase shrinking followed by resection.
  • The treatment of local recurrence is mainly surgical.
  • If not previously administered, radiotherapy represents an alternative therapeutic treatment.
  • [MeSH-major] Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Neoadjuvant Therapy. Peritoneum

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21322269.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Kishiwada M, Kawarada Y, Taoka H, Isaji S: Management of advanced pancreatic cancer: staging laparoscopy and immunochemotherapy--a new treatment strategy. Hepatogastroenterology; 2002 Nov-Dec;49(48):1704-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of advanced pancreatic cancer: staging laparoscopy and immunochemotherapy--a new treatment strategy.
  • BACKGROUND/AIMS: Pancreatic cancer remains a challenging disease with a dismal prognosis.
  • This study investigated the effect of two-route immunochemotherapy via artery (2-ICA) and usefulness of staging laparoscopy in the management of advanced cases.
  • METHODOLOGY: Fifty-five patients admitted to our Department between April 1993 and April 2000 for resection of pancreatic cancer were the subjects of this study.
  • Staging laparoscopy was performed in 16 of the patients, and 2-ICA was used to treat three of 16 because they were found to have small liver metastases during staging laparoscopy.
  • RESULTS: According to the TNM staging system (UICC), 9 (56%) in the 16 patients who underwent staging laparoscopy were found to have Stage IVb disease, 4 (25%) to have Stage IVa disease and only 3 (19%) to have Stage III disease.
  • The three patients with small liver metastases received 2-ICA therapy.
  • The metastatic lesions in the liver had completely disappeared in one patient, and decreased to about half the size in the other two cases.
  • CONCLUSIONS: Staging laparoscopy is useful for correctly diagnosing tumor stage in pancreatic cancer patients and selecting appropriate treatment.
  • The 2-ICA therapy is a new and effective method of treatment for advanced cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fluorouracil / therapeutic use. Immunotherapy. Interleukin-2 / therapeutic use. Laparoscopy. Leucovorin / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397771.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Hata M, Sakamoto K, Doneza J, Sumida K, Sugimoto K, Ishiyama S, Takahashi M, Kojima Y, Tomiki Y, Machi J: Improvement of long-term survival of colorectal cancer in Japanese-Americans of Hawaii from 1990 to 2001. Int J Clin Oncol; 2010 Dec;15(6):559-64
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of long-term survival of colorectal cancer in Japanese-Americans of Hawaii from 1990 to 2001.
  • BACKGROUND: To compare the long-term survival of colorectal cancer (CRC) during two 6-year periods using patients with similar characteristics of the same ethnicity in Hawaii.
  • Patients were divided into two groups by date that patients had surgery: Group 1; 1990-1995, and Group 2; 1996-2001 (introduction of newer chemotherapy, aggressive surgery for liver metastases including radiofrequency thermal ablation).
  • There were no differences between two groups in gender, age, anatomic site, carcinoembryonic antigen, tumor size, histologic grade, and TNM stage distribution, including pT, pN, and pM status.
  • Subgroup analyses showed significant difference (p < 0.05) for more advanced cancers (larger tumor, node positive, metastatic disease, poorly differentiated cancer).
  • CONCLUSIONS: In this study of patients with the same ethnicity, the better survival outcome in latter (Group 2) patients suggests improvement of treatment, especially for patients with more advanced and metastatic cancer (stage IV).
  • [MeSH-major] Asian Americans / ethnology. Colorectal Neoplasms / ethnology. Colorectal Neoplasms / mortality. Liver Neoplasms / ethnology. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Carcinoembryonic Antigen / metabolism. Female. Hawaii / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Asian American Health.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S32-43 [14530656.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1400-9 [12818288.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):50-7 [16283566.001]
  • [Cites] J Natl Cancer Inst Monogr. 1999;(26):101-5 [10854493.001]
  • [Cites] Jpn J Clin Oncol. 2001 Aug;31(8):410-4 [11574637.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):629-39 [15983985.001]
  • [Cites] Cancer J. 2006 Jul-Aug;12(4):318-26 [16925977.001]
  • [Cites] J Surg Oncol. 1998 Dec;69(4):235-8 [9881941.001]
  • [Cites] Surgery. 1988 Mar;103(3):278-88 [3278402.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] J Gastrointest Surg. 2001 Sep-Oct;5(5):477-89 [11985998.001]
  • (PMID = 20602136.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


10. Mehrkhani F, Nasiri S, Donboli K, Meysamie A, Hedayat A: Prognostic factors in survival of colorectal cancer patients after surgery. Colorectal Dis; 2009 Feb;11(2):157-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in survival of colorectal cancer patients after surgery.
  • METHOD: From the cancer database of a single referral institution, a total of 1090 patients who had undergone colorectal resection between 1999 and 2002 were identified.
  • Cases with recurrent colorectal cancer or previous history of neoadjuvant chemotherapy were excluded.
  • Criteria studied consisted of age, sex, TNM stage, T-status, nodal status, distant metastasis, histological grade, lymphatic and vascular invasion, tumour location, preoperative carcinoembryonic antigen (CEA) level and liver function tests.
  • RESULTS: The mean survival time for all patients was 42.8 (SEM = 2.8) months.
  • In univariate analysis, patients' age (P < 0.0001), TNM stage (P < 0.0001), T-status (P = 0.015), nodal status (P = 0.016), distant metastasis (P < 0.0001), grade (P = 0.005), lymphatic and vascular invasion (P < 0.0001) and presurgery CEA level > 5 ng/ml (P = 0.021) were found to be predictors that could affect survival.
  • In Cox regression analysis, age (P < 0.0001), TNM stage (P = 0.001) and grade (P = 0.008) were determined as independent prognostic factors of survival.
  • CONCLUSION: Age, TNM stage, T-status, nodal status, distant metastasis, grade, lymphatic and vascular invasion and presurgery CEA level can predict the postsurgical survival rate in patients with colorectal cancer.
  • [MeSH-minor] Age Factors. Aged. Carcinoembryonic Antigen / blood. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2009 Jun;11(5):538-9 [19508520.001]
  • (PMID = 18462239.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


11. Fan ZM, Song D, Wang L, Fu T, Yang M, Liu GJ: [Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer]. Zhonghua Yi Xue Za Zhi; 2007 Jan 9;87(2):93-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer].
  • OBJECTIVE: To study the feasibility of total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer.
  • METHODS: The 20 patients with breast cancer (TNM stage I, 6 patients; stage II, 14 patients) underwent the total mastectomy axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis.
  • Post-operation they were given chemotherapy, radiotherapy, endocrine therapy.
  • One patient suffered from multiple metastasis of liver and bone nine months after the operation, who has living five years now.
  • CONCLUSION: Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis on selected patients with breast cancer is an oncologically acceptable procedure with superior cosmetic results, without increasing the risk of local recurrences, complications and influencing the effects of postoperative adjuvant treatment.
  • [MeSH-minor] Adult. Feasibility Studies. Female. Follow-Up Studies. Humans. Neoplasm Staging. Nipples / surgery

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418014.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The primary outcome measures of the study were (1) to assess the radiological tumor response;.
  • The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any.
  • METHODS: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • According to the AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II, 39 (24.68%) of them diagnosed at late stage II or early stage III and 112 (70.87%) of them diagnosed at late stage III or stage IV.
  • According to the RECIST criteria, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases.
  • These participants did not receive any other conventional or investigational cancer treatments.
  • The participants report no side effects from the drug psorinum.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.
  • Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Liang JT, Lai HS, Lee PH: Laparoscopic medial-to-lateral approach for the curative resection of right-sided colon cancer. Ann Surg Oncol; 2007 Jun;14(6):1878-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic medial-to-lateral approach for the curative resection of right-sided colon cancer.
  • INTRODUCTION: Our previous randomized clinical trial comparing the laparoscopic medial-to-lateral dissection with the more classic lateral-to-medial approach for resection of rectosigmoid cancer showed that the medial approach reduces the operative time and the postoperative proinflammatory response.
  • Encouraged by the above-mentioned positive findings, we therefore further conduct this phase II clinical trial to examine the feasibility and surgical outcomes regarding the utilization of this medial-to-lateral laparoscopic dissection approach for the curative resection of right-sided colon cancer.
  • METHODS: A total of 104 patients (from December 2000 to January, 2005) with advanced right-sided colon cancer (TNM stage II: n = 56; stage III: n = 48) requiring a curative right hemicolectomy were subjected to the laparoscopic medial-to-lateral approach that included initial exploration and ligation of ileocolic, right colic, and middle colic vessels in no-touch isolation fashion, subsequent medial-to-lateral extension of retroperitoneal dissection along Gerota fascia, opening of lesser sac by transection of gastrocolic ligament, and the final mobilization of hepatic flexure and lateral attachments of ascending colon (Fig. 1).
  • Postoperatively, adjuvant chemotherapy with Mayo Clinic Regimen was given in patients with stage III diseases.
  • RESULTS: The laparoscopic medial-to-lateral approach for a curative right hemicolectomy can be preformed with acceptable operation time (192.6 +/- 32.8 min, mean +/- standard deviation) and little blood loss (48.4 +/- 14.4 ml) through a small wound (6.0 +/- 0.8 cm).
  • During the follow-up periods (median: 30 months, range 6-55 months), recurrence of tumor developed in 6 (10.7%) of stage II and 10 (20.8%) of stage III patients, with liver metastasis in six patients, lung metastasis in 4, liver and lung metastasis in 1, intraperitoneal recurrence in 2, bone metastasis in 1, brain metastasis in 1, and port-site recurrence in 1.
  • [MeSH-minor] Blood Loss, Surgical. Chemotherapy, Adjuvant. Dissection / methods. Feasibility Studies. Follow-Up Studies. Hospitalization. Humans. Ileus / etiology. Ligaments / surgery. Ligation. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Pain, Postoperative / etiology. Postoperative Complications. Prospective Studies. Recovery of Function / physiology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377832.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Yamashita H, Kitayama J, Taguri M, Nagawa H: Effect of preoperative hyperfibrinogenemia on recurrence of colorectal cancer without a systemic inflammatory response. World J Surg; 2009 Jun;33(6):1298-305
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of preoperative hyperfibrinogenemia on recurrence of colorectal cancer without a systemic inflammatory response.
  • Patients with colorectal cancer (CRC) have been shown to have abnormal data for various coagulation tests.
  • METHODS: We retrospectively analyzed the relation between the preoperative plasma fibrinogen level and tumor recurrence in 569 patients with CRC who underwent curative surgical resection and were followed up without adjuvant chemotherapy.
  • RESULTS: The plasma fibrinogen level showed a positive association with tumor recurrence, age, sex, T stage, and TNM classification.
  • When divided with the median value, hyperfibrinogenemia is positively correlated with tumor recurrence, although it lost independence in the multivariate analysis.
  • In the C-reactive protein (CRP)-negative population, hyperfibrinogenemia is independently correlated with tumor recurrence and recurrence-free survival.
  • CONCLUSIONS: Hyperfibrinogenemia is clinically relevant in tumor recurrence before a systemic inflammatory response and thus can be a useful predictor of recurrence in the preinflammatory stage of CRC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brain Neoplasms / secondary. C-Reactive Protein / analysis. Carcinoembryonic Antigen / blood. Female. Humans. Inflammation / blood. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / secondary. Retrospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2003 Jan;133(1):24-31 [12563234.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):484-92 [14752071.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):55-9 [9208961.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):215-9 [12555298.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] N Engl J Med. 1978 Aug 31;299(9):448-51 [683276.001]
  • [Cites] Thromb Haemost. 2002 Mar;87(3):402-8 [11916070.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6966-72 [12460914.001]
  • [Cites] Blood. 2003 Jan 15;101(2):545-51 [12393563.001]
  • [Cites] Thromb Haemost. 1990 Dec 28;64(4):501-5 [1964750.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2184-92 [15917383.001]
  • [Cites] Jpn J Clin Oncol. 2005 Oct;35(10):595-600 [16186176.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48487-90 [15337754.001]
  • [Cites] Oncology. 1995 Sep-Oct;52(5):381-4 [7637955.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1369-79 [10389921.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):314-6 [1998473.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):167-70 [11979429.001]
  • [Cites] Cancer. 1990 May 1;65(9):2055-7 [1695546.001]
  • [Cites] Jpn J Clin Oncol. 2001 Aug;31(8):388-94 [11574632.001]
  • [Cites] Am J Clin Oncol. 1996 Aug;19(4):408-15 [8677916.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):12-6 [10770562.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Sep;20(3):407-12 [11718222.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Sep;27(9):544-6 [16438853.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):237-44 [16675478.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1295-300 [10096562.001]
  • [Cites] Am J Surg. 1998 Oct;176(4):335-8 [9817250.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1447-56 [2778478.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3302-9 [11071621.001]
  • [Cites] Acta Haematol. 2001;106(1-2):25-32 [11549774.001]
  • [Cites] Int J Cancer. 2002 Oct 20;101(6):545-8 [12237895.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):375-82 [6370155.001]
  • [Cites] BMC Cancer. 2006 Jun 01;6:147 [16740157.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):77-82 [15221991.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Apr;15(4):369-73 [12655256.001]
  • [Cites] Blood. 2005 Jan 1;105(1):178-85 [15367435.001]
  • (PMID = 19347392.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 9001-32-5 / Fibrinogen; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


15. Wada I, Shimizu N, Seto Y: [Treatment of neuroendocrine tumors of the digestive tract]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1606-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of neuroendocrine tumors of the digestive tract].
  • Neuroendocrine tumors of the digestive tract are relatively rare and comprise benign and malignant tumors.
  • European Neuroendocrine Tumor Society(ENETS)proposed grading system and TNM classification system with disease staging for endocrine tumors of each organ which are both valid tools for prognostic stratification.
  • The only curative therapy is the complete resection of the tumor.
  • Complete surgical resection of liver metastases is associated with better long-term survival.
  • Combination chemotherapy, such as Etoposide+Cisplatin/Carboplatin, is useful in treating unresected neuroendocrine carcinomas.
  • Octreotide and Pasireotide (SOM230), somatostatin analogues, are reported to have the benefit of both hormonal symptom control and tumor growth suppression.
  • Development of new effective drug is expected for the treatment of neuroendocrine tumors of the digestive tract.
  • [MeSH-major] Antinematodal Agents / therapeutic use. Digestive System Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838017.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antinematodal Agents
  •  go-up   go-down


16. Malik IA: Clinicopathological features and management of gallbladder cancer in Pakistan: a prospective study of 233 cases. J Gastroenterol Hepatol; 2003 Aug;18(8):950-3
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and management of gallbladder cancer in Pakistan: a prospective study of 233 cases.
  • BACKGROUND AND AIMS: Gallbladder cancer is common in Pakistan and has an extremely poor prognosis.
  • Treatment is primarily surgical.
  • Chemotherapy is frequently used in patients with advanced disease.
  • This study was performed to evaluate and compare the clinicopathological features and management of gallbladder cancer in Pakistani patients, with particular emphasis on factors that influence survival.
  • METHODS: Two hundred and thirty-three patients with histologically proven gallbladder cancer were studied.
  • Information was prospectively collected on demographic features, clinical and laboratory findings at the time of presentation, influence of therapy, and survival.
  • However, on multivariate analysis, tumor node metastases (TNM) stage was the only factor influencing survival.
  • Systemic therapy did not provide any survival benefit.
  • The TNM stage remains the most important factor influencing survival.
  • [MeSH-major] Adenocarcinoma / therapy. Gallbladder Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Liver Function Tests. Logistic Models. Male. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Prognosis. Prospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12859725.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. Zhao DB, Gao JD, Shan Y, Zhou ZX, Yuan XH, Wu JX, Shao YF: [Characteristics of metastasis and recurrence following curative resection for colonic carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul;9(4):291-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gross classification,histological type, differentiation, lymph node metastasis were correlated with metastasis/recurrence.
  • Univariate analysis revealed that gross classification, histological type, differentiation, lymph node metastasis, blood vessel invasion, TNM Stage, postoperative chemotherapy, portal chemotherapy were prognostic factors.
  • Cox regression analysis revealed that only gross classification, lymph node metastasis, postoperative chemotherapy, portal chemotherapy were independent prognostic factors.
  • CONCLUSIONS: Liver is the most common metastatic site after curative resection for colonic carcinoma.
  • Gross classification, lymph node metastasis, postoperative chemotherapy, and portal chemotherapy are independent prognostic factors.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886105.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Cusnir M, Patt YZ: Novel systemic therapy options for hepatocellular carcinoma. Cancer J; 2004 Mar-Apr;10(2):97-103
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel systemic therapy options for hepatocellular carcinoma.
  • The prognosis of patients with this cancer has been poor and even tumor resection has rarely been curative.
  • However, orthotopic liver transplantation (OLT) has been associated with long-term survival benefit and cures, provided rigorous patient-selection criteria were adhered to.
  • Liver cirrhosis is the most common precursor for HCC, and attempts have been made to prevent the progression from liver cirrhosis to HCC.
  • Post resection adjuvant therapies have included interferon, polyprenoic acid, and adoptive immunotherapy.
  • Finding effective systemic treatments for non-resectable HCC has been challenging and quite frustrating.
  • The presence of liver cirrhosis and the associated volume expansion, electrolyte imbalances, decreased liver synthetic and metabolic reserve, and portal hypertension has made the design of systemic therapy for HCC a major challenge.
  • Additionally staging of HCC using the Tumor Node Metastases (TNM) system, but ignoring the underlying liver disease made it extremely difficult to compare results of different trials.
  • However by and large it would seem, that the more aggressive chemotherapy agents and combinations were associated with median survival times of 3-5 months.
  • Considering the vascular nature of HCC it may be reasonable to combine tolerable chemotherapy with newly released agents with angiogenesis inhibiting properties.
  • Thus, systemic therapy of HCC is a work in progress that calls for additional trials of tolerable newer agents and combinations.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cancer Vaccines / administration & dosage. Chemotherapy, Adjuvant. Humans. Interferons / therapeutic use. Retinoids / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15130269.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Retinoids; 9008-11-1 / Interferons
  • [Number-of-references] 73
  •  go-up   go-down


19. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology; 2006 Aug;131(2):461-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: During the last 8 years, a nationwide prospective cohort study was performed in 8510 patients with unresectable HCC who underwent TACE using emulsion of lipiodol and anticancer agents followed by gelatin sponge particles as an initial treatment.
  • Exclusion criteria were extrahepatic metastases and/or any previous treatment prior to the present TACE.
  • Both the degree of liver damage and the tumor-node-metastasis (TNM) system proposed by the Liver Cancer Study Group of Japan demonstrated good stratification of survivals (P = .0001).
  • The multivariate analyses showed significant difference in degree of liver damage (P = .0001), alpha-fetoprotein value (P = .0001), maximum tumor size (P = .0001), number of lesions (P = .0001), and portal vein invasion (P = .0001).
  • The last 3 factors could be replaced by TNM stage.
  • The TACE-related mortality rate after the initial therapy was .5%.
  • CONCLUSIONS: TACE showed safe therapeutic modality with a 5-year survival of 26% for unresectable HCC patients.
  • The degrees of liver damage, TNM stage, and alpha-fetoprotein values were independent risk factors for patient survival.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Contrast Media / administration & dosage. Iodized Oil / administration & dosage. Liver Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Injections, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890600.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 8001-40-9 / Iodized Oil
  •  go-up   go-down


20. Capirci C, Rubello D, Chierichetti F, Crepaldi G, Carpi A, Nicolini A, Mandoliti G, Polico C: Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother; 2004 Oct;58(8):451-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multimodality treatment of loco-regional advanced rectal cancer has demonstrated to improve local control and overall survival.
  • Proctoscopy, digital rectal examination (DRE), computer tomography (CT), endorectal ultrasound (ERUS), and magnetic resonance imaging (MRI) cannot correctly detect downstaging in rectal tumors after chemo radiation therapy (CRT).
  • Aim of the present study was to further investigate the accuracy and predictive value of 18F-FDG PET in a large series of patients with rectal cancer treated with preoperative intensified CRT.
  • Between January 2000 and December 2003, 81 patients with histologically proven adenocarcinoma in clinical stage II-III disease, according to criteria of TNM classification, were included in this study.
  • All patients were submitted to diagnostic staging workup with DRE, proctoscopy with biopsy, ERUS, CT scan of the abdomen and pelvis or pelvic MRI plus liver ultrasonography, coloscopy or barium colonic enema.
  • Moreover a pathologic assessment of tumor regression was made with tumor regression grade score (TRG).
  • The accurate identification of rectal cancer patients with major pathological response after preoperative CRT further supports the necessity of designing prospective studies with new and more accurate was imaging technologies with the main object of offering conservative treatment in responder patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464875.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = BiomeĢdecine & pharmacotheĢrapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement